Second autologous transplant as salvage therapy in multiple myeloma

British Journal of Haematology

Volumn 163, Issue 5, 2013, Pages 565-572

  Atanackovic, Djordje ^a   Schilling, Georgia ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Autologous transplantation; Multiple myeloma; Relapse; Salvage therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CARBOPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ETOPOSIDE; LENALIDOMIDE; MELPHALAN; THALIDOMIDE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; DOSE RESPONSE; DRUG MEGADOSE; HUMAN; INFECTION; INTERMETHOD COMPARISON; MAINTENANCE THERAPY; MULTIPLE MYELOMA; NEPHROTOXICITY; OVERALL SURVIVAL; PATIENT SAFETY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETREATMENT; REVIEW; SALVAGE THERAPY; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

AUTOLOGOUS TRANSPLANTATION; MULTIPLE MYELOMA; RELAPSE; SALVAGE THERAPY;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; BORONIC ACIDS; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; HUMANS; INTERFERON-ALPHA; MAINTENANCE CHEMOTHERAPY; MULTICENTER STUDIES AS TOPIC; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PYRAZINES; RECURRENCE; REOPERATION; RETROSPECTIVE STUDIES; SALVAGE THERAPY; THALIDOMIDE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84887614854     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12579     Document Type: Review

References (53)

1. Alvares, C.L., Davies, F.E., Horton, C., Patel, G., Powles, R. & Morgan, G.J. (2006) The role of second autografts in the management of myeloma at first relapse. Haematologica, 91, 141-142.
2. Attal, M., Harousseau, J.L., Stoppa, A.M., Sotto, J.J., Fuzibet, J.G., Rossi, J.F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., Payen, C. & Bataille, R. (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. New England Journal of Medicine, 335, 91-97.
3. Attal, M., Harousseau, J.L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., Voillat, L., Sotto, J.J., Grosbois, B. & Bataille, R. (2003) Single versus double autologous stem-cell transplantation for multiple myeloma. New England Journal of Medicine, 349, 2495-2502.
4. Auner, H.W., Szydlo, R., Rone, A., Chaidos, A., Giles, C., Kanfer, E., Macdonald, D.H., Marin, D., Milojkovic, D., Pavlu, J., Apperley, J.F. & Rahemtulla, A. (2013) Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation. Leukaemia & Lymphoma, 54, 2200-2204.
5. Belch, A., Shelley, W., Bergsagel, D., Wilson, K., Klimo, P., White, D. & Willan, A. (1988) A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. British Journal of Cancer, 57, 94-99.
6. Bird, J.M., Owen, R.G., D'Sa, S., Snowden, J.A., Pratt, G., Ashcroft, J., Yong, K., Cook, G., Feyler, S., Davies, F., Morgan, G., Cavenagh, J., Low, E. & Behrens, J. (2011) Guidelines for the diagnosis and management of multiple myeloma 2011. British Journal of Haematology, 154, 32-75.
7. Blade, J., Cibeira, M.T., Fernandez de Larrea, C. & Rosinol, L. (2010) Multiple myeloma. Annals of Oncology, 21 Suppl 7, vii313-vii319.
8. Blimark, C., Veskovski, L., Westin, J., Rodjer, S., Brune, M., Hjorth, M., Holmberg, E., Andersson, P.O. & Mellqvist, U.H. (2011) Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation. European Journal of Haematology, 87, 117-122.
9. Burzynski, J.A., Toro, J.J., Patel, R.C., Lee, S., Greene, R.E., Ochoa-Bayona, J.L., Frei, C.R. & Freytes, C.O. (2009) Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma. Leukaemia & Lymphoma, 50, 1442-1447.
10. Cavo, M., Tosi, P., Zamagni, E., Cellini, C., Tacchetti, P., Patriarca, F., Di Raimondo, F., Volpe, E., Ronconi, S., Cangini, D., Narni, F., Carubelli, A., Masini, L., Catalano, L., Fiacchini, M., de Vivo, A., Gozzetti, A., Lazzaro, A., Tura, S. & Baccarani, M. (2007) Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. Journal of Clinical Oncology, 25, 2434-2441.
11. Child, J.A., Morgan, G.J., Davies, F.E., Owen, R.G., Bell, S.E., Hawkins, K., Brown, J., Drayson, M.T. & Selby, P.J. (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. New England Journal of Medicine, 348, 1875-1883.
12. Chow, A.W., Lee, C.H., Hiwase, D.K., To, L.B. & Horvath, N. (2013) Relapsed multiple myeloma: who benefits from salvage autografts? Internal Medicine Journal, 43, 156-161.
13. Cook, G., Liakopoulou, E., Pearce, R., Cavet, J., Morgan, G.J., Kirkland, K., Lee, J., Davies, F.E., Hall, R., Rahemtulla, A., Russell, N. & Marks, D.I. (2011) Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma: a study from the British Society of Blood and Marrow Transplantation Registry. Biol Blood Marrow Transplant, 17, 1638-1645.
14. Corso, A., Varettoni, M., Mangiacavalli, S., Zappasodi, P., Pica, G.M., Algarotti, A., Pascutto, C. & Lazzarino, M. (2009) Bortezomib plus dexamethasone is highly effective in relapsed and refractory myeloma patients but responses are short-lived. European Journal of Haematology, 83, 449-454.
15. Dimopoulos, M.A., Zervas, K., Kouvatseas, G., Galani, E., Grigoraki, V., Kiamouris, C., Vervessou, E., Samantas, E., Papadimitriou, C., Economou, O., Gika, D., Panayiotidis, P., Christakis, I. & Anagnostopoulos, N. (2001) Thalidomide and dexamethasone combination for refractory multiple myeloma. Annals of Oncology, 12, 991-995.
16. Dimopoulos, M., Spencer, A., Attal, M., Prince, H.M., Harousseau, J.L., Dmoszynska, A., San Miguel, J., Hellmann, A., Facon, T., Foa, R., Corso, A., Masliak, Z., Olesnyckyj, M., Yu, Z., Patin, J., Zeldis, J.B. & Knight, R.D. (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. New England Journal of Medicine, 357, 2123-2132.
17. Elice, F., Raimondi, R., Tosetto, A., D'Emilio, A., Di Bona, E., Piccin, A. & Rodeghiero, F. (2006) Prolonged overall survival with second on-demand autologous transplant in multiple myeloma. American Journal of Hematology, 81, 426-431.
18. Fenk, R., Liese, V., Neubauer, F., Bruns, I., Kondakci, M., Balleisen, S., Saure, C., Schroder, T., Haas, R. & Kobbe, G. (2011) Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation. Leukaemia & Lymphoma, 52, 1455-1462.
19. Fermand, J.P., Ravaud, P., Chevret, S., Divine, M., Leblond, V., Belanger, C., Macro, M., Pertuiset, E., Dreyfus, F., Mariette, X., Boccacio, C. & Brouet, J.C. (1998) High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood, 92, 3131-3136.
20. Garderet, L., Iacobelli, S., Moreau, P., Dib, M., Lafon, I., Niederwieser, D., Masszi, T., Fontan, J., Michallet, M., Gratwohl, A., Milone, G., Doyen, C., Pegourie, B., Hajek, R., Casassus, P., Kolb, B., Chaleteix, C., Hertenstein, B., Onida, F., Ludwig, H., Ketterer, N., Koenecke, C., van Os, M., Mohty, M., Cakana, A., Gorin, N.C., de Witte, T., Harousseau, J.L., Morris, C. & Gahrton, G. (2012) Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology, 30, 2475-2482.
21. Gonsalves, W.I., Gertz, M.A., Lacy, M.Q., Dispenzieri, A., Hayman, S.R., Buadi, F.K., Dingli, D., Hogan, W.J. & Kumar, S.K. (2013) Second auto-SCT for treatment of relapsed multiple myeloma. Bone Marrow Transplantation, 48, 568-573.
22. Gray, R. & Wheatley, K. (1991) How to avoid bias when comparing bone marrow transplantation with chemotherapy. Bone Marrow Transplantation, 7, 9-12.
23. Harousseau, J.L., Attal, M., Divine, M., Marit, G., Leblond, V., Stoppa, A.M., Bourhis, J.H., Caillot, D., Boasson, M., Abgrall, J.F., Facon, T., Linessier, C., Cahn, J.Y., Lamy, T., Troussard, X., Gratecos, N., Pignon, B., Auzanneau, G. & Bataille, R. (1995) Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French Registry on autologous transplantation in multiple myeloma. Blood, 85, 3077-3085.
24. Harousseau, J.L., Avet-Loiseau, H., Attal, M., Charbonnel, C., Garban, F., Hulin, C., Michallet, M., Facon, T., Garderet, L., Marit, G., Ketterer, N., Lamy, T., Voillat, L., Guilhot, F., Doyen, C., Mathiot, C. & Moreau, P. (2009) Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials. Journal of Clinical Oncology, 27, 5720-5726.
25. Jimenez-Zepeda, V.H., Mikhael, J., Winter, A., Franke, N., Masih-Khan, E., Trudel, S., Chen, C., Kukreti, V. & Reece, D.E. (2012) Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival. Biol Blood Marrow Transplant, 18, 773-779.
26. Johnsen, H.E., Bjorkstrand, B., Carlson, K., Gruber, A., Blystad, A., Fast, A., Boesen, A.M., Bjorkholm, M., Sallerfors, B., Ruutu, T., Carneskog, J., Malm, A., Geisler, C., Lehtinen, M., Schroder, H., Brinch, L., Remes, K., Tidefelt, U., Heilmann, C., Hornsten, P., Thorling, K. & Daugaard, G. (1996) Outcome for patients with leukemia, multiple myeloma and lymphoma who relapse after high dose therapy and autologous stem cell support. Leukaemia & Lymphoma, 24, 81-91.
27. Krejci, M., Adam, Z., Buchler, T., Krivanova, A., Pour, L., Zahradova, L., Holanek, M., Sandecka, V., Mayer, J., Vorlicek, J. & Hajek, R. (2010) Salvage treatment with upfront melphalan 100 mg/m(2) and consolidation with novel drugs for fulminant progression of multiple myeloma. Annals of Hematology, 89, 483-487.
28. Krivanova, A., Hajek, R., Krejci, M., Scudla, V., Indrak, K., Bacovsky, J., Buchler, T., Svobodnik, A., Adam, Z., Mayer, J. & Vorlicek, J. (2004) Second autologous transplantation for multiple myeloma patients relapsing after the first autograft - a pilot study for the evaluation of experimental maintenance therapies. Report of the prospective non-randomized pilot study of the Czech Myeloma Group. Onkologie, 27, 275-279.
29. Lahuerta, J.J., Grande, C., Martinez-Lopez, J., De La Serna, J., Toscano, R., Ortiz, M.C., Larregla, S., Conde, E., Insunza, A., Gonzalez-San Miguel, J.D., Bargay, J., Cabrera, R., Garcia-Ruiz, J.C., Albo, C., Garcia-Alonso, L., Solano, F., Vivancos, P., Leon, A. & San Miguel, J. (2003) Tandem transplants with different high-dose regimens improve the complete remission rates in multiple myeloma. Results of a Grupo Espanol de Sindromes Linfoproliferativos/Trasplante Autologo de Medula Osea phase II trial. British Journal of Haematology, 120, 296-303.
30. Lee, C.K., Barlogie, B., Zangari, M., Fassas, A., Anaissie, E., Morris, C., Van Rhee, F., Cottler-Fox, M., Thertulien, R., Muwalla, F., Mazher, S., Badros, A. & Tricot, G. (2002) Transplantation as salvage therapy for high-risk patients with myeloma in relapse. Bone Marrow Transplantation, 30, 873-878.
31. Lemieux, E., Hulin, C., Caillot, D., Tardy, S., Dorvaux, V., Michel, J., Gastinne, T., Rossi, C., Legouge, C., Touzeau, C., Planche, L., Loirat, M., Lafon, I. & Moreau, P. (2013) Autologous stem cell transplantation: an effective salvage therapy in multiple myeloma. Biol Blood Marrow Transplant, 19, 445-449.
32. Lokhorst, H.M., Wu, K., Verdonck, L.F., Laterveer, L.L., van de Donk, N.W., van Oers, M.H., Cornelissen, J.J. & Schattenberg, A.V. (2004) The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood, 103, 4362-4364.
33. Lokhorst, H., Einsele, H., Vesole, D., Bruno, B., San Miguel, J., Perez-Simon, J.A., Kroger, N., Moreau, P., Gahrton, G., Gasparetto, C., Giralt, S. & Bensinger, W. (2010) International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. Journal of Clinical Oncology, 28, 4521-4530.
34. Ludwig, H., Bolejack, V., Crowley, J., Blade, J., Miguel, J.S., Kyle, R.A., Rajkumar, S.V., Shimizu, K., Turesson, I., Westin, J., Sonneveld, P., Cavo, M., Boccadoro, M., Palumbo, A., Tosi, P., Harousseau, J.L., Attal, M., Barlogie, B., Stewart, A.K. & Durie, B. (2010) Survival and years of life lost in different age cohorts of patients with multiple myeloma. Journal of Clinical Oncology, 28, 1599-1605.
35. McElwain, T.J. & Powles, R.L. (1983) High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet, 2, 822-824.
36. Mehta, J., Tricot, G., Jagannath, S., Desikan, K.R., Siegel, D., Singhal, S., Munshi, N., Vesole, D., Mattox, S., Bracy, D. & Barlogie, B. (1997) High-dose chemotherapy with carboplatin, cyclophosphamide and etoposide and autologous transplantation for multiple myeloma relapsing after a previous transplant. Bone Marrow Transplantation, 20, 113-116.
37. Moreau, P. & Giralt, S.A. (2012) Optimizing therapy for transplant-eligible patients with newly diagnosed multiple myeloma. Leukemia Research, 36, S13-S18.
38. Moreau, P., Avet-Loiseau, H., Harousseau, J.L. & Attal, M. (2011) Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies. Journal of Clinical Oncology, 29, 1898-1906.
39. Moreau, P., Richardson, P.G., Cavo, M., Orlowski, R.Z., San Miguel, J.F., Palumbo, A. & Harousseau, J.L. (2012) Proteasome inhibitors in multiple myeloma: 10 years later. Blood, 120, 947-959.
40. Murakami, H., Handa, H., Abe, M., Iida, S., Ishii, A., Ishikawa, T., Ishida, T., Oota, M., Ozaki, S., Kosaka, M., Sakai, A., Sawamura, M., Shimazaki, C., Shimizu, K., Takagi, T., Hata, H., Fukuhara, T., Fujii, H., Miyata, A., Wakayama, T. & Takatsuki, K. (2007) Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma. European Journal of Haematology, 79, 234-239.
41. Olin, R.L., Vogl, D.T., Porter, D.L., Luger, S.M., Schuster, S.J., Tsai, D.E., Siegel, D.L., Cook, R.J., Mangan, P.A., Cunningham, K. & Stadtmauer, E.A. (2009) Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma. Bone Marrow Transplantation, 43, 417-422.
42. Palumbo, A., Giaccone, L., Bertola, A., Pregno, P., Bringhen, S., Rus, C., Triolo, S., Gallo, E., Pileri, A. & Boccadoro, M. (2001) Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica, 86, 399-403.
43. Qazilbash, M.H., Saliba, R., De Lima, M., Hosing, C., Couriel, D., Aleman, A., Roden, L., Champlin, R. & Giralt, S.A. (2006) Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer, 106, 1084-1089.
44. Quach, H., Kalff, A. & Spencer, A. (2012) Lenalidomide in multiple myeloma: Current status and future potential. American Journal of Hematology, 87, 1089-1095.
45. Rajkumar, S.V. (2011) Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. American Journal of Hematology, 86, 57-65.
46. Reece, D.E., Leitch, H.A., Atkins, H., Voralia, M., Canning, L.A., LeBlanc, R., Belch, A.R., White, D. & Kovacs, M.J. (2008) Treatment of relapsed and refractory myeloma. Leukaemia & Lymphoma, 49, 1470-1485.
47. Richardson, P.G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S.V., Srkalovic, G., Alsina, M., Alexanian, R., Siegel, D., Orlowski, R.Z., Kuter, D., Limentani, S.A., Lee, S., Hideshima, T., Esseltine, D.L., Kauffman, M., Adams, J., Schenkein, D.P. & Anderson, K.C. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. New England Journal of Medicine, 348, 2609-2617.
48. San-Miguel, J.F. & Mateos, M.V. (2011) Can multiple myeloma become a curable disease? Haematologica, 96, 1246-1248.
49. Shah, N., Ahmed, F., Bashir, Q., Qureshi, S., Dinh, Y., Rondon, G., Wen, S., Thall, P., Khan, H., Giralt, S., Champlin, R. & Qazilbash, M.H. (2012) Durable remission with salvage second autotransplants in patients with multiple myeloma. Cancer, 118, 3549-3555.
50. Terpos, E., Mihou, D., Szydlo, R., Tsimirika, K., Karkantaris, C., Politou, M., Voskaridou, E., Rahemtulla, A., Dimopoulos, M.A. & Zervas, K. (2005) The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. Leukemia, 19, 1969-1976.
51. Tricot, G., Jagannath, S., Vesole, D.H., Crowley, J. & Barlogie, B. (1995) Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy. Bone Marrow Transplantation, 16, 7-11.
52. Turesson, I., Velez, R., Kristinsson, S.Y. & Landgren, O. (2010) Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. Journal of Clinical Oncology, 28, 830-834.
53. Weber, D.M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E.A., Siegel, D., Borrello, I., Rajkumar, S.V., Chanan-Khan, A.A., Lonial, S., Yu, Z., Patin, J., Olesnyckyj, M., Zeldis, J.B. & Knight, R.D. (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. New England Journal of Medicine, 357, 2133-2142.